Literature DB >> 2961788

Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia.

R Gerli1, C Riccardi, I Nicoletti, S Orlandi, C Cernetti, F Spinozzi, P Rambotti.   

Abstract

The phenotype and function of T cells circulating in patients with pathological hyperprolactinemia were analyzed and compared to those in sex- and age-matched control subjects. Two-color immunofluorescence study revealed an increased number of CD4+ TQ1+ cells and the presence of phenotypically immature CD1+ T cells, also exhibiting transferrin surface receptor, in peripheral blood of the hyperprolactinemic patients. After chronic treatment with the dopamine agonist bromocriptine, T-cell abnormalities disappeared. In addition, some untreated patients showed enhanced T-cell suppressor activity in an in vitro pokeweed mitogen-driven B-cell transformation assay. These immunological findings confirm a link between neuroendocrine and immune systems in humans.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2961788     DOI： 10.1007/bf00915056

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  28 in total

1.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

2.  The thymus-brain connection: interactions between thymosin and the neuroendocrine system.

Authors:  N R Hall; A L Goldstein
Journal:  Lymphokine Res       Date:  1983

3.  A mature thymocyte-like phenotypic pattern on human cord circulating T-lymphoid cells.

Authors:  R Gerli; P Rambotti; C Cernetti; A Velardi; F Spinozzi; A Tabilio; M F Martelli; F Grignani; S Davis
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

4.  Evidence for the ontogenic precedence of suppressor T cell functions in the human neonate.

Authors:  U Andersson; S Britton; M De Ley; G Bird
Journal:  Eur J Immunol       Date:  1983-01       Impact factor: 5.532

5.  Monoclonal antibody-defined T-cell phenotypes and phytohemagglutinin reactivity of E-rosette-forming circulating lymphocytes from untreated chronic myelocytic leukemia patients.

Authors:  A Velardi; P Rambotti; C Cernetti; F Spinozzi; R Gerli; M F Martelli; S Davis
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

6.  Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine.

Authors:  D H Russell; R Kibler; L Matrisian; D F Larson; B Poulos; B E Magun
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

7.  Immunomodulation in rats by transplantable anterior pituitary tumors.

Authors:  E Nagy; H G Friesen; A H Sehon; I Berczi
Journal:  Endocrinology       Date:  1985-03       Impact factor: 4.736

8.  Phenotypic dissection of cord blood immunoregulatory T-cell subsets by using a two-color immunofluorescence study.

Authors:  R Gerli; A Bertotto; F Spinozzi; C Cernetti; F Grignani; P Rambotti
Journal:  Clin Immunol Immunopathol       Date:  1986-09

9.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin.

Authors:  R Sutherland; D Delia; C Schneider; R Newman; J Kemshead; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  Human T cell subpopulations defined by a monoclonal antibody. I. A small subset is responsible for proliferation to allogeneic cells or to soluble antigens and for helper activity for B cell differentiation.

Authors:  G Corte; M C Mingari; A Moretta; G Damiani; L Moretta; A Bargellesi
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422
View more
  3 in total

Review 1.  Seasonal changes in vertebrate immune activity: mediation by physiological trade-offs.

Authors:  Lynn B Martin; Zachary M Weil; Randy J Nelson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-27       Impact factor: 6.237

2.  Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient.

Authors:  A Vidaller; F Guadarrama; L Llorente; J B Méndez; F Larrea; A R Villa; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

Review 3.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.